Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults

CONCLUSION: An in-development PCV21 vaccine would likely be economically and clinically favorable compared to currently recommended pneumococcal vaccines in older adults. While PCV21 was more favorable in Black cohort analyses, results for both Black and non-Black populations were economically reasonable, highlighting the potential importance of adult-specific pneumococcal vaccine formulations and, pending further investigation, potentially justifying a future general population recommendation for PCV21 use in older adults.PMID:37316409 | DOI:10.1016/j.vaccine.2023.06.007

Source: Vaccine - June 14, 2023 Category: Allergy & Immunology Authors: Angela R Wateska Mary Patricia Nowalk Chyongchiou J Lin Lee H Harrison William Schaffner Richard K Zimmerman Kenneth J Smith Source Type: research